Translating Hidden Gems Into Medicines https://lnkd.in/eZwemAr5 "I know that drug discovery requires a fighting spirit with the curiosity and an open mindset of a bold explorer who looks beyond the obvious." - Louise Modis, Ph.D.?
关于我们
Life Science Leader magazine is an essential business journal for life science executives who work for everything from emerging biotechs to Big Pharmas. Our content is designed to inform readers of industry best practices and motivate them to implement those practices in their businesses. Each month, Life Science Leader features interviews with executives from the leading pharma and biotech companies, including Pfizer, Merck, Daiichi Sankyo, Genentech, Genzyme, Eli Lilly, and Janssen, as well as the FDA and more. This exclusive thought leadership provides an in-depth look into industry trends and hot topics that will impact the growth of the pharma and biopharma markets. As the market is continually growing and innovating, these insights provide readers with actionable information and strategies to implement when navigating the evolving clinical, manufacturing, entrepreneurial, and regulatory landscapes. Life Science Leader is part of Life Science Connect. Life Science Connect Mission: To connect the people, ideas, and organizations needed to advance the development of pharmaceuticals, biologics, diagnostics, and medical devices that improve the human condition so that they can be brought to market in a safe and cost-effective manner.
- 网站
-
https://www.lifescienceleader.com
Life Science Leader的外部链接
- 所属行业
- 图书期刊出版业
- 规模
- 11-50 人
- 总部
- Erie，PA
- 类型
- 私人持股
- 创立
- 2009
- 领域
- Magazine Publishing、Pharmaceutical Business、Biopharmaceutical Business和Biotech
地点
-
主要
获取路线
5340 Fryling Rd.
Suite 100
US，PA，Erie，16510
Life Science Leader员工
动态
-
Drug Development Under Pressure: CEOs Address IRA’s Ripple Effects at Galien Forum 2024 https://lnkd.in/euyKdz7N The “amount of money it takes to get a drug to market only goes up every year, but the total reward we get over the years keeps shrinking. We’re going to have to figure out how to make ourselves a lot more efficient.” - Christopher Viehbacher, president and CEO at Biogen
-
-
Life Science Leader Newsletter: 11.18.24 -- 11.18.24 -- Partnering To Advance Next Generation Treatments For Breast Cancer https://lnkd.in/eTyap8qT Subscribe here: https://lnkd.in/dk4juAsN
-
-
CEO Panel Talks IRA Impact At Galien Forum https://lnkd.in/ev3VxhK5 - By?Ben Comer, Chief Editor, Life Science Leader Christopher Viehbacher, president and CEO at Biogen, began by grousing about the “20% tax on Medicare sales”?coming into effect in 2025, noting that “for those of us looking at our annual operating plans for next year, that is coming into play.”
-
-
Now Is The Time For Philanthropic Venture Capital https://lnkd.in/ediiQbqe It takes about 10 years and upwards of a billion dollars to move a drug candidate from the lab through the clinic to commercial approval.
-
Is Cash Pay The Right Model For Your Medicine? https://lnkd.in/e__YqmpG - By John Amos, CEO, VIVUS LLC Customers now expect their healthcare experience to be quick and easy and expect pharmacies to be able to offer the same type of frictionless customer service experience they’ve come to expect in all their e-commerce transactions.
-
-
Science Does Not Sell Itself: Designing A Winning Pivotal Trial https://lnkd.in/ert24xJa - By Dr. Simone Seiter, Kevin Baruzzi, and Christian M. Hinneburg Simply developing a promising therapeutic based on great science is not enough.
-
-
Partnering To Advance Next Generation Treatments For Breast Cancer https://lnkd.in/e7wt-fs5 - By Kelly Page, Arvinas and Christina Derleth, Pfizer Currently, it is estimated that around 200,000 women in the U.S. are living with metastatic breast cancer.
-
-
From Bike Mechanic To Surgeon To CEO https://lnkd.in/er9-GA_e "I realize now that my passion for helping people with scientific discoveries, curiosity, and persistence are three pillars that have shaped my career." - Niels Riedemann, M.D.
-
-
Science Does Not Sell Itself: Designing A Winning Pivotal Trial https://lnkd.in/ehTTW3SZ - By Dr. Simone Seiter, Kevin Baruzzi, and Christian M. Hinneburg Simply developing a promising therapeutic based on great science is not enough.
-